

## <u>Cardiac amyloidosis – a significant blind spot of the H2FPEF score</u>

Franz Duca, MD, PhD¹; Rene Rettl, MD¹; Christina Binder, MD¹; Fabian Dusik¹; Lore Schrutka, MD, PhD¹; Daniel Dalos, MD, PhD¹; Begüm Öztürk, MD¹; Christophe Denis Josef Capelle, MD¹; Hong Qin, MSc¹; Theresa Marie Dachs, MD¹; Luciana Camuz Ligios DVM¹; Hermine Agis, MD²; Renate Kain, MD, PhD³; Christian Hengstenberg, MD¹; Roza Badr-Eslam, MD¹; Johannes Kastner, MD¹; Diana Bonderman, MD¹,

- <sup>1</sup> Medical University of Vienna, Department of Internal Medicine II, Division of Cardiology, Vienna, Austria
- <sup>2</sup> Medical University of Vienna, Clinical Institute of Pathology, Vienna, Austria
- <sup>3</sup> Medical University of Vienna, Department of Internal Medicine I, Division of Oncology, Vienna, Austria

Cardiac amyloidosis (CA) often presents as heart failure with preserved ejection fraction (HFpEF). The recently published H<sub>2</sub>FPEF score, which consist of clinical and echocardiographic parameters aims to assess the probability of HFpEF in patients with dyspnea. We aimed to investigate the diagnostic utility of the H<sub>2</sub>FPEF score in patients with confirmed HFpEF, cardiac transthyretin (ATTR), and light chain (AL) amyloidosis.

## Materials & Methods

**Background** 


H2FPEF scores were calculated for HFpEF, ATTR, as well as AL amyloidosis patients and divided into low (0-1 points), intermediate (2-5 points), and high (6-9 points) score ranges. Low score ranges allow a rule-out of HF, while high score ranges allow a rule-in. Patients in the intermediate score range would need to undergo further diagnostic assessment.

## <u>Results</u>

187 (100 HFpEF, 87 CA) patients were included into our analyses. Median  $H_2$ FPEF scores were highest among HFpEF (5 points) patients, followed by ATTR (4 points), and AL CA (3 points). Low  $H_2$ FPEF scores were only found among patients in the AL cohort (29.4%), but not among HFpEF or ATTR patients (<0.001). The majority of patients, irrespective of disease entity were in the intermediate score range (HFpEF: 80.0% ATTR: 94.3%, AL: 67.9%; p=0.006). High scores were most often found among HFpEF patients (20.0%), followed by ATTR (5.7%) and AL (2.9%), (p=0.007)].

## Conclusion

The H<sub>2</sub>FPEF score should be used with caution, as there is not only a significant overlap between HFpEF and CA patients, but also 29.4% of AL CA patients would have been misdiagnosed.



<sup>&</sup>lt;sup>4</sup>Klinik Favoriten, Division of Cardiology, Vienna, Austria.